Skip to main content
OpenTrials
Completed

NCT Number: NCT04756960

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

30 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Covance - Clinical Research Unit

Leeds, LS2 9LH, United Kingdom

About this study

This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.

The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.

Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject's written informed consent obtained prior to any study-related procedure;
  • Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
  • Male subjects aged 30 to 55 years inclusive;
  • Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
  • Non- or ex-smoker who smoked < 5 pack years and who stopped smoking > 1 year prior to screening;
  • Good physical and mental status;
  • Vital signs at screening within limits;
  • 12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;
  • Lung function measurements within normal limits at screening;
  • Regular bowel movements at screening;
  • Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.

Exclusion criteria

  • Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
  • Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
  • Clinically relevant abnormal laboratory values;
  • Subjects with history of breathing problems;
  • Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
  • Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening;
  • Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
  • Positive urine test for cotinine;
  • Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
  • Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
  • Intake of non-permitted concomitant medications in the predefined period;
  • Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
  • Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
  • Unsuitable veins for repeated venipuncture;
  • Heavy caffeine drinker;
  • Abnormal haemoglobin level at screening;
  • Subjects using e-cigarettes within 6 months prior to screening;
  • Subjects been involved in a study involving a 14^C-labeled drug within the 12 months prior to enrollment;
  • Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
  • Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.

Treatment and study plan

CHF6001

Drug

4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of [14^C]-labelled CHF6001

Primary outcomes

  1. PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    AUC(0-t_iv) for [14^C] total in plasma.

    AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.

  2. PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    C(max_iv) for [14^C] total in plasma.

    C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration

  3. PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    t(max_iv) for [14^C] total.

    t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

  4. PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Area under curve extrapolated to infinity (AUC(0-∞_iv) for [14^C] total in plasma.

    AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

  5. PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Terminal half-life t(1/2_iv) for [14^C] total and CHF6001.

    t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration

  6. PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

    Blood to plasma ratio for [14^C] total.

  7. PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    AUC(0-t_iv) for [14^C] CHF6001 in plasma.

    AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration

  8. PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    C(max_iv) for [14^C] CHF6001 in plasma.

    C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration

  9. PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    t(max_iv) for [14^C] CHF6001.

    t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

  10. PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Area under curve extrapolated to infinity (AUC0-∞_iv) for [14^C] CHF6001 in plasma.

    AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

  11. PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Terminal half-life t(1/2_iv) for [14^C] CHF6001 in plasma.

    t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration

  12. PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Volume of distribution during the terminal phase (Vz_iv) of [14^C] CHF6001 in plasma.

    Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration

  13. PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Vdss_iv=Volume of distribution is calculated at steady-state for [14^C] CHF6001 in plasma, after intravenous (iv) infusion administration.

  14. PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

    Systemic plasma clearance for [14^C] CHF6001.

  15. PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

    Blood to plasma ratio for [14^C] CHF6001.

  16. PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

    AUC(0-t)_inh for CHF6001 in plasma.

    AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001

  17. PK Parameter -- C(max_inh) -- Plasma -- CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

    C(max_inh) for CHF6001 in plasma.

    C(max_inh)=Peak plasma concentration after inhalation of CHF6001

  18. PK Parameter -- t(max_inh) -- Plasma -- CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

    t(max_inh) for CHF6001 in plasma.

    t(max_inh)=Time to reach the Cmax after inhalation of CHF6001

  19. PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

    AUC(0-∞_inh) for CHF6001 in plasma.

    AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001

  20. PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001

    Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

    t(1/2_inh) for CHF6001 in plasma.

    t(1/2_inh)=Terminal half-life, after inhalation of CHF6001

  21. PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001

    Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

    Absolute inhaled bioavailability for CHF6001.

    F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).

  22. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total

    Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.

    Urine excreted fraction for cumulative [14^C] total.

  23. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001

    Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.

    Urine excreted fraction for cumulative [14^C]-CHF6001.

    Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.

  24. PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total

    Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

    Fecal excreted fraction for cumulative [14^C] total.

  25. PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001

    Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

    Fecal excreted fraction for cumulative [14^C]-CHF6001.

  26. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total

    Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

    Urine and fecal excreted fraction for cumulative [14^C] total.

  27. PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001

    Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

    Urine and Fecal excreted fraction for cumulative [14^C]-CHF6001.

Sponsors and collaborators

Lead sponsor

Chiesi Farmaceutici S.p.A.

Industry

Registry information

Official study title

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 Following a Single Inhaled Dose Co-administered With an Intravenous Radiolabelled Microtracer Dose in Healthy Volunteers

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Feb 16, 2021
Registry last updated
Mar 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.